Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial - Wikidata - wikimedia - TriplyDB

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

http://www.wikidata.org/entity/Q34737471

about

Burkitt lymphoma in adolescents and young adults: management challenges.Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications.Treating adults with acute lymphocytic leukemia: new pharmacotherapy options.Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010 Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survival Central nervous system involvement in AIDS-related lymphomas New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia.A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling.Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children.Adolescent and young adult non-Hodgkin lymphoma.Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science.Human lymphocytic B-leukemia cell line treatment with the bacterial toxin listeriolysin O and rituximab (anti-CD20 antibody): Effects of similar localization of their receptors.A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B-cell lymphoma.Burkitt leukemia limited to the bone marrow has a better prognosis than Burkitt lymphoma with bone marrow involvement in adults.Peripheral blood lymphocyte to monocyte ratio identifies high-risk adult patients with sporadic Burkitt lymphoma.Personalized medicine in adult acute lymphoblastic leukemia.Rituximab in the management of acute lymphoblastic leukemia.Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers.Relapsed/refractory Burkitt lymphoma and HIV infection.The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma.Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets.Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice.Frondoside A induces AIF-associated caspase-independent apoptosis in Burkitt lymphoma cells.A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration.Incidence and risk factors for relapses in HIV-associated non-Hodgkin-lymphoma as observed in the German HIV-related lymphoma cohort study.Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma.Comprehensive genomic characterization dissects the complex biology of a case of synchronous Burkitt lymphoma and myeloid malignancy with shared hematopoietic ancestry.Genetic differences between paediatric and adult Burkitt lymphomas.Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group

P2860

Q30238965-BE7C61A0-1332-4550-AEA1-3125C110C779 Q30240133-AD8D8E6F-199E-4288-93E9-E2DD9FC61705 Q30243925-E3CC6427-EDF1-4533-95E2-949EF8CF496B Q35236068-8156FF7C-44F1-48D6-BAEC-F4C99DBE4553 Q36931139-152551C6-E0C7-4010-8E6F-D7C490341964 Q36989459-3E6381E5-DF1E-4A28-BA8F-F240FCA90981 Q38428357-033E4038-B523-4E39-972F-D80A3DC3BF8F Q38465823-18DDEDCA-6C0F-4505-BEF7-BB4169C38BFD Q38640263-5DB5FCF0-1955-4D78-BBB0-FC36D399D914 Q38722432-9158F136-ECF6-4CE6-BA60-87BDFD48BCA0 Q38782141-0785E3D9-BBC2-41B6-BCEF-27399F9075E5 Q38806478-9291CBAD-15AF-49DA-8CB6-1B8641414E08 Q38813978-3CB1DF5A-E546-4A25-837E-8CA2D6DB89D9 Q38822525-1458FB75-B5BD-4CA3-8674-E55984079E33 Q38848737-A7259CEF-89EF-40C7-AF9B-ADC80073AFDA Q40690632-CC69E011-8507-45E9-AC7E-500EAAC1BDAD Q41244407-DE243154-38BC-4007-8BBF-868E01DAE42E Q41663533-AA51F7E0-59B6-4CAD-BB66-EB6D5322BDFE Q42384621-9088F398-4106-4D84-A8C5-38867CC81FC6 Q47196522-1D6CBBCF-F6C2-489A-AA6A-C4CB984EFC80 Q47361098-26A3518F-4FE0-4C57-8BE2-C493E5D06AF0 Q47368952-608EFFC8-2BEE-4992-8029-1802F1A90DB4 Q47562321-C62C4EA1-FF88-4D83-82C3-252673D734C3 Q47563526-5B875BE4-D345-432F-A1DF-5FF28C620162 Q47571040-FE9B733E-F9BE-435B-B4CD-865AA1B5F35F Q47951320-B73D0DBB-AF4A-4A5A-AD92-86E81D83B91E Q48138574-8215F82F-E589-40BF-A5CB-75B7C8851A25 Q48254769-850C6FB9-337B-4E1E-A806-B6055BC010EB Q50035090-2FE51CA9-115B-4E24-9F91-05F2DB3B9AF9 Q51556801-EFFCD4C6-453F-472A-A39E-7E256C338954 Q52547022-D07F5F34-7E8E-46D8-9D81-050828E01A05 Q53174284-CF40812E-FB28-44E9-B0B0-1633E24E9F19 Q55283747-CEA09F4A-7705-4532-94D5-866E659FD8DF Q57174502-70D3F3E5-B372-4BA4-90EF-7147207FC759 Q58801965-A8B1E509-F4DC-4214-AF41-728F78F2CBB0

P2860

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

http://www.wikidata.org/entity/Q34737471

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Improved outcome of adult Burk ...... prospective multicenter trial

@ast

Improved outcome of adult Burk ...... prospective multicenter trial

@en

Improved outcome of adult Burk ...... prospective multicenter trial

@nl

type

label

Improved outcome of adult Burk ...... prospective multicenter trial

@ast

Improved outcome of adult Burk ...... prospective multicenter trial

@en

Improved outcome of adult Burk ...... prospective multicenter trial

@nl

prefLabel

Improved outcome of adult Burk ...... prospective multicenter trial

@ast

Improved outcome of adult Burk ...... prospective multicenter trial

@en

Improved outcome of adult Burk ...... prospective multicenter trial

@nl

P1433

Q34737471-D862065E-764C-4723-B302-91492ED93D70

P1476

Q34737471-CD2EF6A3-6071-4FE9-8298-434274A12FC6

P2093

Q34737471-22E5C3F2-0CE3-4AA5-B04E-85C27FAE785E

Q34737471-33BF893B-BB96-414A-A146-89BBA303EDE7

Q34737471-3B89D466-1CA0-4933-9327-11184BE91CE2

Q34737471-43EC5E9E-E785-46FF-B9DC-24B0B48CB20A

Q34737471-6CFFCF18-3857-48B9-867F-5A882D173AB5

Q34737471-74022FE8-59B0-4A48-BCE9-66DD3B2B64D7

Q34737471-8531AAAA-2941-42DC-963B-24B13913A94C

Q34737471-8618EA42-66F3-4A19-A783-C81522CDC063

Q34737471-99F8919A-B8FE-49F0-B2BA-1E4FBDFD7DF9

Q34737471-B947CC51-3621-4077-81CC-8B8E90B1DDFE

P2860

Q34737471-13B6B414-2FCD-4619-A38D-687845EFD018

Q34737471-152643DE-D0C1-4878-A4B8-7FB975CE871B

Q34737471-2124258C-C1AF-43E5-9E85-775BCFE79776

Q34737471-26024C91-372E-4FE9-8300-C5C2D0E2D9F7

Q34737471-306F2A28-0B3B-411E-A28E-9FD2FF219ACD

Q34737471-37FAC4DB-2DD1-4CEB-B0DB-02AC5427ECD4

Q34737471-44E59193-D8F2-4758-B5AD-61DF0FAEEA75

Q34737471-533EDFD2-79F0-499B-B83F-687DADB29AB7

Q34737471-641967D5-67D0-4A7D-815E-B6586199A00A

Q34737471-66335BBB-36E2-4703-8D7D-96C03EB79EB1

P304

Q34737471-0EBECEF7-5D57-4FD5-AC2F-4464BD79135F

P31

Q34737471-00F3D669-3E74-4AE2-84F7-3019106547B6

P356

Q34737471-F96DFB01-5970-47B9-ADBF-CD752A81A17F

P407

Q34737471-4436F848-0C55-4BF2-8699-A9F09B14E33C

P433

Q34737471-5B890A39-A4A0-4713-991D-DE7BA39204C4

P478

Q34737471-65544828-12B8-4EE5-BC9A-91A61CFF1D0A

P50

Q34737471-092FA400-8461-44B6-9525-165862E6DB2A

Q34737471-10B87AC0-F080-46C7-A0AF-6882C61BDE44

Q34737471-38BBF499-C587-4E92-B2EC-6E96CCB52027

Q34737471-68B4A86D-4EF6-4933-919A-5A72BC05DFD3

Q34737471-B9EA3F23-53D2-4FE4-BA7E-84D39D011C7B

Q34737471-F68EF54A-7D6A-45E3-8BE7-ADE8043677E5

P577

Q34737471-497E9D8C-DAB7-45A7-9FD0-B8F386A29353

P5875

Q34737471-12531022-3D27-4175-9E89-C6B6E474D41D

P698

Q34737471-683CEC67-AA26-45C4-8457-3E022860041F

P921

Q34737471-3957DE79-BF8D-4EAE-9F91-0B6E863457E0

Q34737471-99769777-4A82-40E4-8D5C-3B774059D949

Q34737471-A312F56A-29A2-4CE7-9164-CFA87DF22936

Q34737471-E43D85CF-AA22-4DC0-8233-5D4E2B1DA47D

P932

Q34737471-B8018AAA-1B36-4AF7-A38B-12C4C6137A79

P356

BLOOD-2014-03-563627

P1433

P1476

Improved outcome of adult Burk ...... prospective multicenter trial

@en

P2093

Albrecht Reichle

http://www.w3.org/2001/XMLSchema#string

Andreas Viardot

http://www.w3.org/2001/XMLSchema#string

Bernd Hertenstein

http://www.w3.org/2001/XMLSchema#string

Dieter Hoelzer

http://www.w3.org/2001/XMLSchema#string

Eckhard Thiel

http://www.w3.org/2001/XMLSchema#string

German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia

http://www.w3.org/2001/XMLSchema#string

Harald Rieder

http://www.w3.org/2001/XMLSchema#string

Heinz-August Horst

http://www.w3.org/2001/XMLSchema#string

Ingo G H Schmidt-Wolf

http://www.w3.org/2001/XMLSchema#string

Jan Walewski

http://www.w3.org/2001/XMLSchema#string

P2860

A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases.

Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.

Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.

Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.

Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol.

Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia.

P304

3870-3879

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2014-03-563627

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

Nicola Gökbuget

Thomas Burmeister

Andreas Hüttmann

Hartmut Döhner

P577

2014-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267738229

http://www.w3.org/2001/XMLSchema#string

P698

25359988

http://www.w3.org/2001/XMLSchema#string

P921

Burkitt lymphoma

multicenter trial

P932

4271177

http://www.w3.org/2001/XMLSchema#string